Cloud Pharma and THERAMetrics collaborate on targeting orphan CNS diseases

Cloud Pharmaceuticals, a US cloud-based drug design and development company, and Switzerland-based THERAMetrics Holding (SIX: TMX) today announced a strategic collaboration focusing on the design and development of therapeutics for orphan central nervous system (CNS) diseases and other indications.

The partnership will initially focus on orphan diseases such as Huntington’s disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). In parallel to these efforts, both companies will pursue sponsored development for additional respiratory indications.

THERAMetrics will employ its innovative DRR 2.0 technology to identify novel protein targets, which are produced by the genes responsible for certain pathologies. Cloud Pharmaceuticals will apply its Quantum Molecular Design(sm) process to design small molecular compounds and peptides that inhibit the activity of those targets. It is intended that Cloud Pharmaceuticals will manage early drug development efforts of lead compounds and THERAMetrics’ contract research organization business unit will manage clinical research.